

**EFFECTIVE DATE:** 02|15|2016  
**POLICY LAST UPDATED:** 10|04|2018

## OVERVIEW

Intensity-modulated radiotherapy (IMRT) may be an integral component in the treatment of cancers of the abdomen and pelvis. IMRT has been proposed as a method of radiotherapy that allows adequate radiation to the tumor while minimizing the radiation dose to surrounding normal tissues and critical structures.

## MEDICAL CRITERIA

### BlueCHiP for Medicare and Commercial Products

Intensity-modulated radiotherapy may be considered **medically necessary** as an approach to delivering radiotherapy for patients with cancer of the anus/anal canal.

When dosimetric planning with standard 3-dimensional conformal radiotherapy predicts that the radiation dose to an adjacent organ would result in unacceptable normal tissue toxicity, IMRT may be considered **medically necessary** for the treatment of cancer of the abdomen and pelvis, including but not limited to:

- stomach (gastric);
- hepatobiliary tract;
- pancreas;
- rectal locations; or
- gynecologic tumors (including cervical, endometrial, and vulvar cancers).

## PRIOR AUTHORIZATION

Prior authorization is required for BlueCHiP for Medicare and recommended for Commercial Products via the online tool for participating providers.

## POLICY STATEMENT

### BlueCHiP for Medicare and Commercial Products

Intensity-modulated radiotherapy of the abdomen and pelvis may be considered medically necessary when the criteria above is met.

IMRT is considered not covered for BlueCHiP for Medicare and not medically necessary for Commercial Products for all other uses in the abdomen and pelvis.

## COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable radiology benefits/coverage.

## BACKGROUND

### Radiation Techniques

#### Conventional External-Beam Radiotherapy

Methods to plan and deliver radiotherapy have evolved in ways that permit more precise targeting of tumors with complex geometries. Most early trials used 2-dimensional treatment planning, based on flat images and radiation beams with cross-sections of uniform intensity that were sequentially aimed at the tumor along 2 or 3 intersecting axes. Collectively, these methods are termed conventional external-beam radiotherapy.

### **Three-Dimensional Conformal Radiation**

Treatment planning evolved by using 3-dimensional images, usually from computed tomography (CT) scans, to delineate the boundaries of the tumor and discriminate tumor tissue from adjacent normal tissue and nearby organs at risk for radiation damage. Computer algorithms were developed to estimate cumulative radiation dose delivered to each volume of interest by summing the contribution from each shaped beam. Methods also were developed to position the patient and the radiation portal reproducibly for each fraction and immobilize the patient, thus maintaining consistent beam axes across treatment sessions. Collectively, these methods are termed 3-dimensional conformal radiotherapy (3D-CRT).

### **Intensity-Modulated Radiotherapy**

IMRT uses computer software and CT and magnetic resonance images, to offer better conformality than 3D-CRT, because it modulates the intensity of the overlapping radiation beams projected on the target and uses multiple shaped treatment fields. Treatment planning and delivery are more complex, time-consuming, and labor intensive for IMRT than for 3D-CRT. The technique uses a multileaf collimator [MLC]), which, when coupled with a computer algorithm, allows for “inverse” treatment planning. The radiation oncologist delineates the target on each slice of a CT scan and specifies the target’s prescribed radiation dose, acceptable limits of dose heterogeneity within the target volume, adjacent normal tissue volumes to avoid, and acceptable dose limits within the normal tissues. Based on these parameters and a digitally reconstructed radiographic image of the tumor, surrounding tissues, and organs at risk, computer software optimizes the location, shape, and intensities of the beam ports to achieve the treatment plan’s goals.

Increased conformality may permit escalated tumor doses without increasing normal tissue toxicity and thus may improve local tumor control, with decreased exposure to surrounding normal tissues, potentially reducing acute and late radiation toxicities. Better dose homogeneity within the target may also improve local tumor control by avoiding underdosing within the tumor and may decrease toxicity by avoiding overdosing.

Technologic development has produced advanced techniques that may further improve RT treatment by improving dose distribution. These techniques are considered variations of IMRT. Volumetric modulated arc therapy delivers radiation from a continuous rotation of the radiation source. The principal advantage of volumetric modulated arc therapy is greater efficiency in treatment delivery time, reducing radiation exposure and improving target radiation delivery due to less patient motion. Image-guided RT involves the incorporation of imaging before and/or during treatment to more precisely deliver RT to the target volume.

IMRT methods to plan and deliver RT are not uniform. IMRT may use beams that remain on as MLCs move around the patient (dynamic MLC) or that are off during movement and turn on once the MLC reaches prespecified positions (“step and shoot” technique). A third alternative uses a very narrow single beam that moves spirally around the patient (tomotherapy). Each method uses different computer algorithms to plan treatment and yields somewhat different dose distributions in and outside the target. Patient position can alter target shape and thus affect treatment plans. Treatment plans are usually based on a single imaging scan, a static 3D-CT image. Current methods seek to reduce positional uncertainty for tumors and adjacent normal tissues by various techniques. Patient immobilization cradles and skin or bony markers are used to minimize day-to-day variability in patient positioning. In addition, many tumors have irregular edges that preclude drawing tight margins on CT scan slices when radiation oncologists contour the tumor volume. It is unknown whether omitting some tumor cells or including some normal cells in the resulting target affects outcomes of IMRT.

Note that the evidence for the following abdominal and pelvic cancers has not yet been reviewed and is beyond the scope of this review: bladder, kidney, ureter, and esophageal cancer and sarcoma.

### **CODING**

#### **BlueCHiP for Medicare and Commercial Products**

**A4648:** Tissue marker, implantable, any type, each (Note: This code is not separately reimbursed for institutional providers.)

**Note:** To ensure correct pricing of HCPC code **A4648** for the Calypso 4D localization system, the procedure/clinical notes and the invoice must be submitted.

The following codes are covered for BlueCHiP for Medicare and commercial products when the criteria above is met:

**Intensity-modulated radiation therapy**

- 77301:** Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
- 77338:** Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
- 77385:** Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple (Institutional providers)
- 77386:** Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex (Institutional providers)
- G6015:** Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session: (Professional providers)
- G6016:** Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session: (Professional providers)

**RELATED POLICIES**

- Preauthorization via Web-Based Tool for Procedures
- Intensity Modulated Radiotherapy: Cancer of the Head, Neck and Thyroid
- Intensity Modulated Radiotherapy: Central Nervous System Tumors
- Intensity Modulated Radiotherapy: Breast and Lung
- Intensity Modulated Radiotherapy: Prostate

**PUBLISHED**

- Provider Update, December 2018
- Provider Update, October 2017
- Provider Update, October 2017
- Provider Update, February 2016
- Provider Update, November 2015

**REFERENCES**

1. Boda-Heggemann J, Hofheinz RD, Weiss C, et al. Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. *Int J Radiat Oncol Biol Phys.* Nov 15 2009;75(4):1187-1195. PMID 19409725
2. Boda-Heggemann J, Weiss C, Schneider V, et al. Adjuvant IMRT/XELOX radiochemotherapy improves longterm overall- and disease-free survival in advanced gastric cancer. *Strahlenther Onkol.* May 2013; 189(5):417-423. PMID 23558673
3. Fuller CD, Dang ND, Wang SJ, et al. Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: Initial clinical results. *Radiother Oncol.* Aug 2009;92(2):249-254. PMID 19324442
4. Lee KJ, Yoon HI, Chung MJ, et al. A comparison of gastrointestinal toxicities between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for pancreatic cancer. *Gut Liver.* Mar 23 2016;10(2):303-309. PMID 26470767
5. Prasad S, Cambridge L, Huguet F, et al. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. *Pract Radiat Oncol.* Mar-Apr 2016;6(2):78-85. PMID 26577010
6. Naik A, Gurjar OP, Gupta KL, et al. Comparison of dosimetric parameters and acute toxicity of intensitymodulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study. *Cancer Radiother.* Jul 2016;20(5):370-376. PMID 27368915

7. Gandhi AK, Sharma DN, Rath GK, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. *Int J Radiat Oncol Biol Phys.* Nov 1 2013;87(3):542-548. PMID 24074927
8. Shih KK, Hajj C, Kollmeier M, et al. Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy. *Gynecol Oncol.* Oct 2016;143(1):18-21. PMID 27486131
9. Chen CC, Wang L, Lu CH, et al. Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy. *J Formos Med Assoc.* Dec 2014;113(12):949-955. PMID 24144528
10. Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. *Int J Radiat Oncol Biol Phys.* Apr 1 2007;67(5):1438-1444. PMID 17394944
11. Rattan R, Kapoor R, Bahl A, et al. Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. *Ann Transl Med.* Feb 2016;4(4):70. PMID 27004217
12. Sun Z, Adam MA, Kim J, et al. Intensity-modulated radiation therapy is not associated with perioperative or survival benefit over 3D-conformal radiotherapy for rectal cancer. *J Gastrointest Surg.* Jan 2017;21(1):106-111. PMID 27510332
13. Huang CM, Huang MY, Tsai HL, et al. A retrospective comparison of outcome and toxicity of preoperative image guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma. *J Radiat Res.* Mar 01 2017;58(2):247-259. PMID 27738080
14. Chuong MD, Freilich JM, Hoffe SE, et al. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. *Gastrointest Cancer Res.* Mar 2013;6(2):39-45. PMID 23745158
15. Dasgupta T, Rothenstein D, Chou JF, et al. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. *Radiother Oncol.* May 2013;107(2):189-194. PMID 23692961
16. Dewas CV, Maingon P, Dalban C, et al. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer? *Radiat Oncol.* Nov 2012;7:201. PMID 23190693
17. Devisetty K, Mell LK, Salama JK, et al. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. *Radiother Oncol.* Nov 2009;93(2):298-301. PMID 19717198
18. Pepek JM, Willett CG, Wu QJ, et al. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. *Int J Radiat Oncol Biol Phys.* Dec 1 2010;78(5):1413-1419. PMID 20231064
19. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Gastric Cancer. Version 2.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/gastric.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf). Accessed May 31, 2018.
20. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Hepatobiliary Cancers. Version 1.2018. [https://www.nccn.org/professionals/physician\\_gls/PDF/hepatobiliary.pdf](https://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf). Accessed May 31, 2018.
21. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Pancreatic Adenocarcinoma. Version 1.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/pancreatic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf). Accessed May 31, 2018.
22. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Cervical Cancer. Version 1.2018. [https://www.nccn.org/professionals/physician\\_gls/PDF/cervical.pdf](https://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf). Accessed May 31, 2018.
23. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Uterine Neoplasms. Version 2.2018. [https://www.nccn.org/professionals/physician\\_gls/PDF/uterine.pdf](https://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf). Accessed May 31, 2018.

24. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Ovarian Cancer. Version 2.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/ovarian.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf). Accessed May 31, 2018.
25. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Anal Carcinoma. Version 1.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/anal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf). Accessed May 31, 2018.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

